1.1 The Aldosterone Synthesis Pathway

Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex. The terminal three steps of biosynthesis are catalyzed by aldosterone synthase (CYP11B2), which converts 11-deoxycorticosterone → corticosterone → 18-hydroxycorticosterone → aldosterone.

The clinical problem: CYP11B2 (aldosterone synthase) and CYP11B1 (11β-hydroxylase) share 93% amino acid sequence similarity [1][2]. CYP11B1 catalyzes the final step of cortisol biosynthesis. A non-selective inhibitor crashes both pathways simultaneously — adrenal insufficiency in exchange for aldosterone suppression.

flowchart TD
    A[Cholesterol] --> B[Pregnenolone]
    B --> C[Progesterone]
    C --> D[11-Deoxycorticosterone]
    D --> E[Cortisol pathway<br/>CYP11B1<br/>11-beta-hydroxylase]
    D --> F[Aldosterone pathway<br/>CYP11B2<br/>aldosterone synthase]
    E --> G[Cortisol]
    F --> H[Corticosterone]
    H --> I[18-OH-corticosterone]
    I --> J[Aldosterone]
    style F fill:#ffe4b5
    style G fill:#e0e0e0
    style J fill:#90ee90

Selective CYP11B2 inhibition (orange highlight) suppresses aldosterone (green) while preserving cortisol (gray).

1.2 Why Osilodrostat (LCI699) Failed for Hypertension

The first attempt at aldosterone synthase inhibition for HTN was osilodrostat (LCI699), originally developed by Novartis. In Phase 2 HTN trials, LCI699 lowered aldosterone and BP — but its CYP11B2:CYP11B1 selectivity ratio was insufficient (approximately 4:1 in some assays). Cortisol suppression was clinically meaningful, with documented blunting of ACTH-stimulated cortisol response. The HTN program was terminated.

LCI699 was later repurposed as osilodrostat for Cushing syndrome (FDA-approved 2020 for Cushing’s), where cortisol suppression IS the therapeutic goal. The HTN effect Novartis saw with LCI699 confirmed that aldosterone synthase inhibition could lower BP — but the molecule needed dramatically better selectivity to be safe for chronic HTN treatment [1][2].

1.3 Baxdrostat — The Selectivity Engineering Advance

Baxdrostat (CIN-107) was engineered for selectivity. Per the published characterization:

The 100:1 selectivity ratio is the engineering achievement that distinguishes baxdrostat from osilodrostat. The Phase 1 PK/safety study (Freeman MW, et al. Hypertens Res 2023) characterized the dose-response and confirmed cortisol preservation at therapeutic exposures [3].

1.4 Pharmacokinetics and Dosing

• Half-life: approximately 29-30 hours (Phase 1 study Freeman 2023 reported 29 hours; BaxHTN main text reports 30 hours) [3][5]. The approved PI (2026) cites a mean effective half-life of approximately 26 hours — the speaker deck uses the 26-hour PI figure. Either way, the long half-life supports once-daily dosing and a degree of missed-dose forgiveness.
• Once-daily oral dosing supported by the long half-life
• Steady state: approximately 5-7 days
• Doses studied: 0.25, 0.5, 1, 2 mg (Phase 1); 0.5 mg / 1 mg / 2 mg (Phase 2 BrigHTN); 1 mg / 2 mg (Phase 3 BaxHTN); 0.5 mg up-titrated to 1 mg low-dose, 2 mg up-titrated to 4 mg high-dose (BAX-CKD)
• Aldosterone suppression begins at doses ≥1.5 mg in healthy volunteers [3]
• Cortisol pathway interference (precursor accumulation) only at doses ≥90 mg — therapeutic doses (1-4 mg) are far below this threshold [5]
• Phase 1 PK study in renal impairment (Freeman et al, single 10 mg dose): three groups stratified by eGFR (≥60, 15-59, <15). No significant impact on systemic exposure or clearance — no dose adjustment needed for renal impairment [5]. Important corollary: the BAX-CKD hyperkalemia signal is pharmacodynamic (drug doing its job too well in already-compromised potassium handling), not pharmacokinetic (excess drug exposure).
• Drug interactions: Baxdrostat inhibits MATE1 and MATE2-K renal transporters. Metformin is a MATE substrate, but a dedicated interaction study showed baxdrostat + metformin combination was well tolerated with no dose adjustment required [5].

1.5 How Much Does Baxdrostat Actually Block Aldosterone Synthase?

Andy’s question — “is it approximately 70%?” — is in the right ballpark; the actual figure at the therapeutic 2 mg daily dose is closer to 60% functional aldosterone suppression. The data come from the BrigHTN Phase 2 trial pharmacodynamic measurements (Freeman 2022, NEJM Figure 3 and Pharmacodynamic Measures section) [1] — FULL-TEXT VERIFIED from the PDF in DEVONthink:

Lower doses showed proportionally less suppression: - 0.5 mg: LSM serum aldosterone difference vs placebo −3.0 ng/dL (95% CI −4.3 to −1.7; equivalent to −83.2 pmol/L), approximately 43% reduction from baseline 6.9 ng/dL - 1 mg: intermediate (graphed in Figure 3 but not quantified as a specific LSM number in the BrigHTN main text) - 2 mg: −4.9 ng/dL serum, −273 ng/g creatinine urinary — the values above

Clinical bottom line:

At the therapeutic 2 mg daily dose, baxdrostat reduces functional aldosterone production by approximately 58-63% (serum and urinary, respectively), based on BrigHTN Phase 2 pharmacodynamic data [1]. It is NOT a complete blockade. The remaining 35-40% of aldosterone production is preserved — and that is mechanistically important. Complete CYP11B2 ablation would cause hypoaldosteronism with severe hyperkalemia and hyponatremia. The partial inhibition is a feature, not a limitation: it suppresses pathologic aldosterone excess while preserving the physiologic baseline needed for sodium and potassium homeostasis.

Citation: Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2022;388(5):395-405. PMID 36342143. PubMed — Figure 3 (panels A, B, C, D) and Pharmacodynamic Measures section. Full-text verified 2026-04-08 from PDF in DEVONthink Research Articles.

1.6 The Sustained Effect Phenomenon

The BaxHTN Phase 3 randomized withdrawal phase revealed a clinically interesting pharmacodynamic finding: BP did not rapidly return to baseline after baxdrostat discontinuation, despite drug clearance within one week [4]. The withdrawal-arm placebo group had only +1.4 mmHg rise vs −3.7 mmHg additional drop in those continuing baxdrostat (difference −5.1 mmHg, P=0.002).

The leading mechanistic interpretation: aldosterone-driven sodium retention and vascular remodeling are slow to reverse. Suppressing aldosterone synthesis allows the kidney to re-establish sodium homeostasis at a lower volume set-point, and this volume effect persists past plasma drug clearance. This is biologically plausible and clinically interesting — but it does raise the question of whether intermittent dosing might preserve efficacy. No data on intermittent dosing exists.

2.1 BrigHTN (Phase 2) — The Proof of Concept

Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med 2022;388(5):395-405. PubMed

Results — change in SBP from baseline:

Safety highlights: - No deaths - No SAEs attributed to baxdrostat - No adrenocortical insufficiency (cortisol preserved) - Hyperkalemia (K ≥6.0 mmol/L) in 2 patients — did not recur after withdrawal and reinitiation - Plasma aldosterone fell dose-dependently, plasma renin rose (expected with aldosterone suppression)

Approximately 46% of the 2 mg group achieved BP control (SBP <130 mmHg) per the secondary endpoint analysis described in the Mlynarska 2025 review [5]. This is comparable to or slightly higher than the BaxHTN Phase 3 BP control rate of 40% in the 2 mg arm.

BrigHTN established proof of concept: baxdrostat lowers BP in resistant HTN with manageable safety [1].

2.2 HALO — The Failure That Matters (Conference Only, Not Peer-Reviewed)

HALO is a Phase 2 trial in uncontrolled (non-resistant) hypertension that DID NOT meet its primary endpoint. The trial enrolled 249 patients and was presented by Deepak Bhatt at the American College of Cardiology (ACC) 2023 Annual Meeting on March 8, 2023, in New Orleans.

HALO trial results (verified from Mlynarska 2025 secondary review, Table 2):

The story is in the placebo column: the placebo arm dropped 16.6 mmHg SBP — far larger than expected for a placebo response. The 2 mg baxdrostat arm achieved −19.8 mmHg, only about 3 mmHg better than placebo, and the difference was not statistically significant. Per the secondary literature, patients with confirmed therapeutic plasma baxdrostat levels DID show a significant SBP reduction, indicating that adherence (not drug efficacy) was the critical variable. This is the key methodological lesson the BaxHTN program then designed around — strict 2-week placebo run-in with adherence verification before randomization.

Per the BaxHTN paper main text [4]:

“However, in a phase 2 trial (HALO) involving patients with uncontrolled hypertension, baxdrostat did not show a between-group difference in the change from baseline to week 8 in seated systolic blood pressure as compared with placebo.”

The leading interpretation across secondary literature [5][6][7] is that the placebo arm in HALO had unexpected BP improvement — likely from the trial-related adherence improvement common in clinical trial settings. In patients with uncontrolled (not strictly resistant) HTN — typically on 1-2 medications — the trial-related adherence improvement was large enough to match the baxdrostat effect.

2.3 BaxHTN (Phase 3) — The Pivotal Positive Trial

Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393(14):1363-1374. PubMed

Primary endpoint results:

BP control endpoint (SBP <130 mmHg at week 12) — VERIFIED FROM TABLE S5:

Effect size in absolute terms: - ARR for BP control (1 mg): 39.4% − 18.7% = 20.7% → NNT ≈ 5 over 12 weeks - ARR for BP control (2 mg): 40.0% − 18.7% = 21.3% → NNT ≈ 5 over 12 weeks

Diastolic BP changes (secondary endpoint, full text Table 2): - 1 mg vs placebo: −3.3 mm Hg (95% CI −5.2 to −1.4), P=0.001 - 2 mg vs placebo: −3.9 mm Hg (95% CI −5.7 to −2.0), P<0.001

Resistant HTN subgroup (n=579, 73% of trial): - 1 mg: placebo-corrected −9.1 mmHg (P<0.001) - 2 mg: placebo-corrected −9.8 mmHg (P<0.001)

The treatment effect was consistent across prespecified subgroups including age, sex, race, baseline BP, diabetes status, and renal function [4].

Randomized withdrawal phase (weeks 24-32): - Patients on open-label 2 mg baxdrostat for weeks 12-24 were re-randomized - Continued baxdrostat: additional −3.7 mmHg SBP reduction - Switched to placebo: +1.4 mmHg rise - Difference: −5.1 mmHg (P=0.002) - Plasma drug cleared within 1 week, but BP effect persisted — interpreted as durable sodium homeostasis effect

Safety profile (12-week data):

Pooled PI adverse-reaction table (12-week, pooled placebo-controlled HTN trials — the label population, eGFR ≥45):

2.3.1 Resistant vs Uncontrolled Hypertension — How the Trials Defined Them

The baxdrostat Phase 3 program turns on the distinction between uncontrolled and resistant hypertension. They are not synonyms, and each trial operationalized them differently. The general (2017/2025 AHA/ACC, 2018 AHA scientific statement) definitions:

• Uncontrolled hypertension (uHTN) — BP above goal regardless of how many agents the patient is on. It is a control status, not a regimen threshold. A patient on one drug who is above goal has uncontrolled HTN.
• Resistant hypertension (rHTN) — BP above goal despite ≥3 antihypertensive agents of different classes at maximally tolerated doses, one of which is a diuretic — OR BP at goal but requiring ≥4 agents (“controlled resistant”). The mandatory diuretic and the three-drug floor separate resistant from merely uncontrolled.
• Apparent treatment-resistant HTN (aTRH) — meets the resistant numeric criteria but pseudoresistance has not yet been excluded (non-adherence, white-coat effect, undertreatment, measurement error). “True” resistant HTN requires excluding pseudoresistance — exactly the job of the placebo run-in (adherence) and ambulatory monitoring (white-coat).

How each baxdrostat trial operationalized entry (design paper: Flack JM et al, Hypertens Res 2025;48(11):2911-2923 DOI; According to PubMed):

2.3.2 Why the Phase 3 Trials Were Designed the Way They Were

Design-rationale source: Flack JM, Azizi M, Brown JM, et al. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025;48(11):2911-2923. DOI (According to PubMed).

The Phase 3 program (BaxHTN, BaxAsia, Bax24) is engineered to answer the one question the Phase 2 HALO failure raised: is the BP drop a real, ongoing drug effect — or trial-related adherence, white-coat effect, and regression to the mean? Every design element is a defense against a specific confounder.

The shared 2-week single-blind placebo run-in (all three trials) is the central design choice. Before randomization it confirms background-med adherence (pill count), filters out placebo responders and pseudoresistance, establishes a reproducible elevated baseline, and stabilizes the regimen so the only thing that changes at randomization is study drug. (In Bax24 the run-in excluded 199 of 854 screened patients — the run-in doing exactly its job.)

BaxHTN and BaxAsia use a 4-part adaptive design after run-in: 1. 12-week double-blind (1:1:1 → 2 mg / 1 mg / placebo) — the primary endpoint, change in seated office SBP at week 12. Two doses characterize dose-response (1 mg captured nearly all the effect → supports a low, safer starting dose). 2. 12-week open-label — everyone destined for the withdrawal phase is first established on 2 mg, creating a stable known-responder population. 3. 8-week randomized withdrawal (re-randomize 2:1 → continue 2 mg vs placebo) — the key secondary (see teaching point). 4. 20-week open-label — one-year safety exposure (K, Na, eGFR, adrenal).

The cohort split (first 450 randomized = Cohort 1, all 4 parts; later = Cohort 2, parts 1–2 only) powers the primary endpoint while limiting how many responders are withdrawn onto placebo in Part 3 — an ethics-and-statistics optimization built into enrollment.

Bax24 is a separate, leaner, confirmatory trial: pure resistant HTN, entry gated on 24-h ambulatory SBP ≥130 (gold-standard confirmation of true resistance), single 2 mg dose, simple 1:1, one clean ambulatory primary. It exists because office BP — BaxHTN’s primary — is vulnerable to white-coat and observer effects; ABPM removes them and captures nocturnal/non-dipping burden. BaxAsia extends the BaxHTN design to an Asia-predominant population for geographic and regulatory breadth.

2.4 Bax24 — Dedicated 24-Hour Ambulatory BP Trial (Phase 3)

Azizi M, Brown JM, Dwyer JP, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988-999. DOI · PubMed (According to PubMed). NCT06168409.

This supersedes the prior “ABPM substudy” placeholder — Bax24 is a stand-alone Phase 3 trial built to confirm the office-BP signal using the gold-standard ambulatory measure.

Primary result:

Safety: adverse events 52% (baxdrostat) vs 37% (placebo); confirmed K >6.0 mmol/L in 3% (3/108) baxdrostat vs 0% placebo.

Secondary endpoints (Bax24) — the around-the-clock story: - 24-h ambulatory SBP <130 mmHg achieved in 71% (60/85) vs 17% (14/84) — odds ratio 15.2 (95% CI 6.6–35.2; P<0.0001); NNT ≈ 2. - Daytime ambulatory SBP −16.8 (−14.1 vs placebo; P<0.0001); nighttime −16.0 (−13.9 vs placebo; P<0.0001) — sustained day and night. - Seated office SBP (secondary) −14.9 mmHg (−10.3 vs placebo; P<0.0001). - Background therapy was heavier than BaxHTN: mean approximately 4 antihypertensives, 100% on a diuretic, approximately 94% on ACEi/ARB.

BaxHTN also ran an optional ABPM substudy (n=56 across 34 sites): baxdrostat 2 mg 24-h ambulatory SBP −16.0 vs placebo +1.0 (difference −16.9 mmHg); pooled nighttime −12.1 (difference −11.7). Small and exploratory — Bax24 is the definitive ambulatory evidence, but BaxHTN’s substudy points the same direction.

2.5 Place in the Resistant Hypertension Treatment Algorithm

flowchart TD
    A[Confirmed resistant HTN: BP above goal on 3+ meds incl diuretic] --> B[Confirm not pseudoresistant]
    B --> C[Out-of-office BP monitoring<br/>Adherence verification<br/>Secondary HTN workup]
    C --> D[Lifestyle: Na restriction, weight, alcohol, exercise]
    D --> E[Optimize current regimen<br/>thiazide → chlorthalidone if eGFR <30 → CLICK trial]
    E --> F[STEP 4: Add MRA<br/>Spironolactone 25-50 mg/day<br/>PATHWAY-2 evidence]
    F --> G{BP at goal?}
    G -->|Yes| H[Continue, monitor K]
    G -->|No| I[STEP 5 alternatives]
    I --> J[Aldosterone synthase inhibitor<br/>Baxdrostat — when FDA approved]
    I --> K[Endothelin receptor antagonist<br/>Aprocitentan]
    I --> L[Renal denervation<br/>SPYRAL HTN-OFF/ON]
    I --> M[Other: doxazosin, clonidine, hydralazine, beta-blocker]

Where baxdrostat fits per current data: - After maximized first-line agents and a diuretic - After MRA trial (spironolactone is cheap, established, and PATHWAY-2 already validated it) - As an alternative when MRA is not tolerated (gynecomastia, hyperkalemia, GFR-driven dose limits) - As an addition to MRA — no published combination data yet - In place of MRA for patients who specifically don’t tolerate the off-target steroid effects of spironolactone

This positioning is consistent with the 2023 KDIGO/ESC and 2025 AHA expanded HTN guideline framework that places MRAs as Step 4 [8][9]. The Phase 3 evidence supports baxdrostat as a Step 5 alternative or add-on.

2.6 FDA Approval Status — APPROVED (2026)

BAXFENDY (baxdrostat) is FDA-approved (PI: AstraZeneca Pharmaceuticals LP, Wilmington DE, 2026) — the first and only FDA-approved aldosterone synthase inhibitor.

Indication (verbatim): an aldosterone synthase inhibitor indicated, in combination with other antihypertensive drugs, for the treatment of hypertension to lower blood pressure in adults who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

• Boxed warning: none. Warnings and precautions: hyperkalemia and hyponatremia — assess potassium and sodium before initiation, correct abnormalities first, monitor periodically; more frequent monitoring if 65 or older, diabetes, CKD, or potassium-raising drugs.
• The label is broad — it does not require failure of an MRA or a specific number of prior agents; the speaker deck positions it as a 3rd-line add-on for adults with SBP greater than 140 mmHg taking 2 or more antihypertensives. See §2.5 for how this reconciles with the evidence-based “reserve after MRA” stance.

2.7 Approved Dosing and Monitoring

3.1 The Mechanistic Case

Aldosterone effects extend beyond sodium retention. Preclinical and clinical evidence supports aldosterone-driven mechanisms in:

These effects are well-established for MRAs (spironolactone, eplerenone, finerenone). The question for baxdrostat is whether suppressing aldosterone production at the source produces the same downstream protective effects as blocking the receptor. Mechanistically, the answer should be yes. Clinically, the data have not yet been generated.

3.2 BAX-CKD / FigHTN Phase 2 — The First CKD-Specific Baxdrostat Trial

Dwyer JP, Maklad N, Vedin O, et al. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol 2026;37(2):299-311. PubMed — FULL-TEXT VERIFIED 2026-04-08.

The trial is formally named FigHTN (per the trial schematic) and informally called BAX-CKD. This is the most clinically relevant trial for the nephrologist audience. Understated in the broader baxdrostat narrative, but critical for Andy’s CKD patient population.

Baseline characteristics — this is a sick CKD population (Table 1, full text verified): - Mean age 67 years (corrected from 66 — actual is 67) - 32% women, 68% male - 80% type 2 diabetes (so this is largely a DKD trial) - 33% Black or African American; 31% Hispanic or Latino; 58% White - Mean baseline SBP 151.2 mmHg, mean baseline DBP 81.1 mmHg - Mean baseline eGFR 44 mL/min/1.73m² (CKD G3b — patients distributed across G2 to G4) - Median UACR 714 mg/g (Q1-Q3: 307-1429); 76% had macroalbuminuria (UACR >300 mg/g) - 42% on SGLT2 inhibitor at baseline (a stratification factor — important context for the K signal below) - 44% on diuretic; 17% on GLP-1 RA - 35% on ACEi only, 61% on ARB only, 4% on neither - Patients on MRAs or potassium-sparing diuretics were EXCLUDED at baseline — important comparator note vs the BaxHTN protocol - Trial was US-only, 78 sites, enrollment April 29, 2022 to May 2, 2024 - 132 of 195 (68%) completed treatment

Primary endpoint result — placebo-corrected SBP change at week 26:

The hyperkalemia signal — granular detail from full text:

The “41% hyperkalemia” headline number is the BROADEST possible definition (any treatment-emergent adverse event the investigator labeled as hyperkalemia). The full text gives much more granularity:

Severity breakdown of hyperkalemia AEs (n=53 events in baxdrostat pooled): - Mild: 27 events (low-dose 13, high-dose 14) - Moderate: 21 events (low-dose 6, high-dose 15) - Severe: 5 events (low-dose 2, high-dose 3)

3.2.1 Hyperkalemia — A Deeper Look (the central issue for nephrology use)

Why CKD amplifies the signal — it is pharmacodynamic, not pharmacokinetic. Aldosterone is the principal hormonal driver of distal-nephron potassium secretion: it activates ENaC in the principal cells, generating the lumen-negative transepithelial voltage that drives K efflux through ROMK, and it upregulates the basolateral Na/K-ATPase. Suppress aldosterone synthesis and you blunt that secretory gradient — serum K rises. In a normal kidney there is ample excretory reserve, so the rise is small (BaxHTN K >6.0 approximately 3% [PMID 40888730]). In CKD the reserve is already spent — fewer functioning nephrons, lower distal flow, frequent concomitant RAAS blockade — so the same degree of aldosterone suppression produces a larger K rise. The renal-impairment PK study (Freeman 2023) showed baxdrostat exposure is not increased in CKD, so this is a pharmacodynamic effect (the drug doing its job in a kidney with no buffer), not drug accumulation. That distinction matters clinically: you cannot dose-adjust your way around it the way you would for a renally-cleared drug — you manage it with potassium handling, co-therapy, and monitoring.

Three populations, three “hyperkalemia” numbers — keep them straight:

The spread from 41% down to 10.2% is almost entirely renal function and dose — not a contradiction. BAX-CKD ran an eGFR approximately 44 population titrated to 4 mg; the label population is eGFR ≥45 on 2 mg.

The label was written to avoid exactly the BAX-CKD risk. The FDA approval (1) sets an eGFR ≥45 floor (safety not established below), (2) offers a 1 mg option for patients at higher hyperkalemia/hyponatremia risk, and (3) caps the dose at 2 mg. BAX-CKD’s worst signal lived precisely where the label does not go — eGFR <45, titrated to 4 mg (high-dose AE 51% vs low-dose 32%). So the on-label hyperkalemia experience is the 10.2% / 3% / 1.8% set, not the 41%. The 41% is the cautionary number for the off-label CKD patient a nephrologist might be tempted to treat.

How it compares with MRAs. In FIDELIO-DKD, finerenone discontinuation for hyperkalemia was 2.3% (vs 0.9% placebo) in a similar proteinuric DKD population [PMID 33264825]; steroidal spironolactone in CKD runs higher. BAX-CKD’s 7% looks worse — but the comparison is not clean: different K thresholds and ascertainment, doses up to 4 mg, and BAX-CKD excluded baseline MRA users while 42% were on an SGLT2 inhibitor (which lowers K). The sobering corollary: a real-world patient on an MRA or not on an SGLT2i could run a higher K risk than the trial showed. Honest read: baxdrostat’s potassium liability in CKD sits in the steroidal-MRA neighborhood — meaningfully above finerenone — and demands the same or greater vigilance.

A practical hyperkalemia protocol if using baxdrostat in a higher-risk patient: - Before starting: confirm eGFR ≥45 (label) and serum K <5.0 (the trials’ ceiling); correct K first; scrub the med list for K-raisers (max-dose RAASi, MRA, K-sparing diuretics, trimethoprim, NSAIDs, K supplements). - Stack K-lowering co-therapy proactively: an SGLT2 inhibitor (also synergistic for BP and proteinuria), a loop or thiazide diuretic, dietary potassium counseling, and a potassium binder (patiromer or sodium zirconium cyclosilicate) held in reserve. - Monitor on the drug’s schedule, not a generic one: the K rise is front-loaded — approximately 0.4 mmol/L in the first 2 weeks, then it plateaus (BaxHTN). Check K and Na at baseline, week 1 to 2, then periodically; more often if 65 or older, diabetic, CKD, or on K-raising drugs (per PI). - Act on thresholds (PI): K 5.5 to 6.0 → mitigate (binder, diuretic, diet) and consider interrupting or reducing to 1 mg; K >6.0 → hold and treat; permanently discontinue if clinically significant hyperkalemia recurs. Re-checking K after any restart is explicitly recommended.

The benefit–risk tension nephrology has to sit with. BAX-CKD’s standout finding was a 55% UACR reduction — a cardiorenal surrogate in the finerenone range — in a population that is 80% diabetic and heavily proteinuric. That is precisely the population that stands to gain the most and the one at the highest potassium risk. Finerenone earned its place by carrying that tension through hard-outcome trials (FIDELIO/FIGARO). Baxdrostat has not run that trial, and the label deliberately stops at eGFR 45 — so for the moderate-to-advanced CKD patient where a nephrologist most wants aldosterone suppression, baxdrostat is today off-label, evidence-limited, and potassium-rate-limited. Whether a dedicated CKD outcomes trial with built-in K mitigation opens that door is the open question that matters most for our specialty.

MAJOR POSITIVE FINDING — UACR reduction (NEW data point not in my initial draft):

This is a major positive cardiorenal data point that was missing from my abstract-level draft. Baxdrostat reduced UACR by approximately 55% from baseline in 26 weeks. For comparison, finerenone in FIDELIO-DKD reduced UACR by approximately 31% at month 4 vs placebo. The baxdrostat UACR effect is in the same range as — possibly larger than — finerenone’s, in a similarly proteinuric CKD population.

eGFR safety (no major signal):

The mean eGFR change of −2.3 mL/min/1.73m² across 26 weeks was NOT statistically significant vs placebo. There was no excess of acute eGFR decline events. This is consistent with an early hemodynamic effect (similar to ACEi/ARB initiation) rather than progressive renal injury — and the changes are reversible per the BaxHTN withdrawal phase data.

No adrenal insufficiency events were reported, confirming cortisol pathway preservation in the CKD population.

BP control rate at week 26 (exploratory): - Pooled baxdrostat: 38/105 (36%) achieved SBP <130 mmHg - Low-dose: 21/50 (42%) - High-dose: 17/55 (31%) - Placebo: 8/48 (17%) - ARR: 36% − 17% = 19%; NNT ≈ 5 over 26 weeks for BP control

3.3 The Finerenone Benchmark — What “Cardiorenal Benefit” Actually Looks Like

For Andy’s audience to understand whether baxdrostat has cardiorenal benefit, the comparator standard is finerenone — a non-steroidal selective MRA with hard outcome trials.

FIDELIO-DKD (Bakris GL, et al. N Engl J Med 2020;383:2219-2229) PubMed - N=5,734 with T2DM and CKD (eGFR 25-75, UACR 30-5000) - Finerenone vs placebo - Primary kidney composite (kidney failure, sustained ≥40% eGFR decline, or renal death): - Finerenone: 17.8% - Placebo: 21.1% - HR 0.82 (95% CI 0.73-0.93, P=0.001) - ARR: 3.4%; NNT ≈ 29 over median 2.6 years - Hyperkalemia leading to discontinuation: 2.3% finerenone vs 0.9% placebo (lower than spironolactone in earlier CKD trials)

FIGARO-DKD (Pitt B, et al. N Engl J Med 2021;385:2252-2263) PubMed - N=7,437 with T2DM and CKD (less advanced than FIDELIO) - Finerenone vs placebo - Primary CV composite (CV death, nonfatal MI, nonfatal stroke, HF hospitalization): - Finerenone: 12.4% - Placebo: 14.2% - HR 0.87 (95% CI 0.76-0.98, P=0.03) - ARR: 1.8%; NNT ≈ 56 over median 3.4 years

These are hard endpoint trials with 5,000-7,000 patients each. Finerenone’s evidence base for DKD is mature. Baxdrostat has nothing equivalent.

3.4 Where ASi Would Fit If Outcome Data Confirm Mechanism

If future trials show baxdrostat reduces hard cardiorenal endpoints (independent of BP), the positioning would be:

flowchart TD
    A[CKD/DKD with proteinuria<br/>eGFR >25, UACR >30] --> B[Foundation: ACEi/ARB max tolerated dose]
    B --> C[Add SGLT2i: dapagliflozin/empagliflozin/canagliflozin]
    C --> D[Add GLP-1 RA if T2DM and eGFR-appropriate: semaglutide]
    D --> E[Add finerenone if eGFR appropriate and K manageable]
    E --> F{BP at goal? Cardiorenal outcomes optimized?}
    F -->|No, BP residual| G[Add baxdrostat — ASi]
    F -->|Hyperkalemia limits MRA| G
    F -->|Yes| H[Continue, monitor]

This is the speculative position. It depends on outcome data baxdrostat has not yet generated.

4.1 No Baxdrostat HF Trials Yet

There are no published baxdrostat trials in heart failure. PubMed search returns nothing for “baxdrostat heart failure” or “baxdrostat HFpEF” as of 2026-04-08. Any HF claims for baxdrostat are mechanistic extrapolation from MRA evidence, not direct trial data.

4.2 The MRA Heart Failure Evidence Base

For Andy’s audience to understand what HF evidence baxdrostat would need to generate:

RALES (Pitt B, et al. N Engl J Med 1999;341:709-717) PubMed - Spironolactone in severe HFrEF (LVEF ≤35%, NYHA III-IV) - N=1,663 - 30% mortality reduction (HR 0.70, P<0.001) - ARR approximately 11%; NNT ≈ 9 over 24 months - The trial that established MRAs as foundational HF therapy

EPHESUS (Pitt B, et al. N Engl J Med 2003;348:1309-1321) PubMed - Eplerenone post-MI with LV dysfunction - N=6,632 - 15% all-cause mortality reduction - Confirmed MRA benefit in post-MI HF

EMPHASIS-HF (Zannad F, et al. N Engl J Med 2011;364:11-21) PubMed - Eplerenone in mild HFrEF (NYHA II) - N=2,737 - 37% reduction in primary endpoint (CV death or HF hospitalization) - Extended MRA benefit to milder HFrEF

TOPCAT (Pitt B, et al. N Engl J Med 2014;370:1383-1392) PubMed - Spironolactone in HFpEF - N=3,445 - Primary endpoint NEUTRAL overall, but Americas region showed benefit (post-hoc) - Quality-control concerns about Russia/Georgia enrollment limited interpretation - The “almost positive” HFpEF MRA trial that drove the field toward FINEARTS-HF

FINEARTS-HF (Solomon SD, et al. N Engl J Med 2024;391:1475-1485) PubMed - Finerenone in HFpEF/HFmrEF (LVEF ≥40%) - N=6,001 - Primary composite (CV death + total worsening HF events): rate ratio 0.84 (95% CI 0.74-0.95, P=0.007) - ARR approximately 3-4% over median 32 months - Established finerenone as the first MRA with positive HFpEF outcome data

4.3 What Baxdrostat Would Need to Show

For baxdrostat to have a HF indication, it would need: 1. A trial in HFrEF showing mortality or hospitalization reduction comparable to RALES/EPHESUS/EMPHASIS-HF 2. OR a trial in HFpEF/HFmrEF showing benefit comparable to FINEARTS-HF 3. With acceptable hyperkalemia and renal safety

No such trial is currently underway publicly. The cardiorenal/metabolism (CVRM) division at AstraZeneca has expressed interest in HF indications, but pivotal trial design and timelines have not been disclosed in the published literature.

4.4 The Mechanistic Story for HF (Honest Version)

Aldosterone is mechanistically implicated in HF pathophysiology — fibrosis, remodeling, sodium retention, sympathetic activation. MRAs are foundational HF therapy for that reason. Suppressing aldosterone production should, in theory, do what MRA receptor blockade does. Whether the source-suppression strategy translates to clinical benefit at the same magnitude is an empirical question, and the empirical work has not been done.

For the 4/21 dinner: do not claim baxdrostat has HF benefit. State the mechanism, state that no HF trials exist, state that the field is interested but the evidence is not yet generated.

5.1 The Aldosterone Case in DKD

Aldosterone-mediated injury contributes to DKD progression independent of glycemic control: - Mesangial expansion - Podocyte effacement - Tubulointerstitial fibrosis - Glomerular hyperfiltration relief from RAAS feedback control

This is the rationale for finerenone, the mineralocorticoid receptor antagonist with the strongest DKD evidence base.

5.2 BAX-CKD as the Effective DKD Trial

Returning to BAX-CKD (Dwyer 2025, JASN) [11]: 80% of the 195 enrolled patients had type 2 diabetes. This is, in practice, a DKD trial.

The BP outcome was positive (−8.1 mmHg pooled). The hyperkalemia signal was prohibitive (41% AE rate). The trial did not report hard renal outcomes. Whether baxdrostat slows eGFR decline or reduces hard kidney endpoints in DKD is unanswered.

5.3 Comparator Evidence Base in DKD

The treatment cascade for DKD has matured rapidly. Andy’s audience should know what baxdrostat is competing against:

SGLT2 inhibitors: - DAPA-CKD (Heerspink HJL, et al. N Engl J Med 2020;383:1436-1446) PubMed — dapagliflozin in CKD with and without diabetes; HR 0.61 for primary kidney composite; ARR approximately 4%; NNT approximately 25 over 2.4 years - EMPA-KIDNEY (EMPA-KIDNEY Collaborative Group. N Engl J Med 2023;388:117-127) PubMed — empagliflozin across broad CKD; HR 0.72 for primary; ARR approximately 4%; NNT approximately 25 over 2 years - CREDENCE (Perkovic V, et al. N Engl J Med 2019;380:2295-2306) PubMed — canagliflozin in DKD; HR 0.70 for renal composite

GLP-1 receptor agonists: - FLOW (Perkovic V, et al. N Engl J Med 2024;391:109-121) PubMed — semaglutide in DKD; HR 0.76 for primary kidney composite; ARR approximately 3.7%; NNT approximately 27 over 3.4 years

Finerenone (FIDELIO-DKD, FIGARO-DKD — see Section 3.3 above)

5.4 Where Baxdrostat Would Fit in DKD

The honest assessment: baxdrostat does not currently have a clear place in DKD beyond BP lowering. The DKD treatment cascade — RAASi + SGLT2i + GLP-1 RA + finerenone — is supported by hard outcome trials. Baxdrostat does not have a hard outcome trial in DKD. Until it does, baxdrostat in DKD should be positioned as:

1. A BP-lowering option when goal is not met after the cascade above
2. An MRA alternative when finerenone is not tolerated (severe hyperkalemia, allergy, cost)
3. NOT as a substitute for finerenone where finerenone is appropriate
4. NOT as a substitute for SGLT2i where SGLT2i is appropriate

The most likely future trial design: a finerenone-style hard endpoint trial in DKD, comparing baxdrostat to placebo on a background of standard care (RAASi + SGLT2i). This would take 3-5 years to read out.

Comparator Evidence (MRAs and Cardiorenal Trials)

13. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. PubMed — FIDELIO-DKD. Primary kidney composite HR 0.82 (95% CI 0.73-0.93, P=0.001); ARR 3.4%, NNT ≈ 29 over 2.6 years.

14. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. PubMed — FIGARO-DKD. Primary CV composite HR 0.87 (95% CI 0.76-0.98, P=0.03); ARR 1.8%, NNT ≈ 56 over 3.4 years.

15. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485. PubMed — FINEARTS-HF. Primary composite (CV death + HF events) RR 0.84 (95% CI 0.74-0.95, P=0.007). Verified PMID 2026-04-08; the prior placeholder PMID 39216093 was incorrect (MATTERHORN mitral valve trial).

16. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717. PubMed — RALES. 30% mortality reduction with spironolactone in NYHA III-IV HFrEF.

17. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. PubMed — EPHESUS. Eplerenone post-MI with LV dysfunction.

18. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. PubMed — EMPHASIS-HF. Eplerenone in mild HFrEF.

19. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. PubMed — TOPCAT. Spironolactone in HFpEF.

20. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. PubMed — DAPA-CKD.

21. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. PubMed — EMPA-KIDNEY.

22. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. PubMed — CREDENCE.

23. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PubMed — FLOW. Semaglutide in DKD.

HFpEF Cardiac Amyloid Diagnostic Trap (Per Andy’s Standards)

24. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis — A clinical challenge. Int J Cardiol. 2020;304:138-143. (Median 13-month diagnostic delay)

25. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2022. (44% initial misdiagnosis rate)

26. Shchendrygina A, et al. Cardiac amyloidosis screening yield in HFpEF cohorts. 2024. (Approximately 10% screening yield in HFpEF)

AstraZeneca Baxfendy Speaker Program (2026)

This review is the clinical background for Andy’s BAXFENDY (baxdrostat) speaker-bureau programs. Program and deliverable cross-links:

• Speaker deck: AZ Baxdrostat Moline 2026 07 14 BAXFENDY Speaker Deck locked.pptx — the locked AZ-approved deck; the Part 3 randomized-withdrawal slide is annotated by the §2.3.2 teaching point above
• Patient companion: Sick Day Baxfendy Patient Handout — sick-day rules handout for patients started on baxdrostat
• Programs: Dubuque 6/16 · Bettendorf 7/9 · Moline 7/14
• Slide-prep blocks: 6/4 review · 6/13 final review
• Engagement project: AstraZeneca Baxdrostat Engagement

Existing Cross-Linked Vault Content (REVISED 2026-04-08)

Re-audited after Andy correctly noted that significant MRA/finerenone/aldosterone-synthase content already exists in the Cardiology and Cardiorenal folders.

EXISTING content to cross-reference (not gaps):

Genuinely missing (deferred for future build): - Dedicated finerenone deep-dive review (covered comprehensively in MRA vs nsMRA vs aldo synthase inhib but a single-drug review would still add value for the cardiorenal teaching audience) - Esaxerenone dedicated review (Japanese market, limited US relevance) - Endothelin pathway in HTN broader review

Author: Andrew Bland, MD, FACP, FAAP Medical Associates Department of Nephrology | University of Illinois College of Medicine at Peoria | University of Dubuque PA Program | Butler College of Osteopathic Medicine All cited trials verified against PubMed. Generated by /medical-review skill in the Dex Personal OS for the AstraZeneca dinner presentation 2026-04-21. Honest evidence-based assessment — distinguishes proven benefit from mechanistic extrapolation. Not promotional content.